Type of diagnosis | Any Px received N | Any anticoagula | GCS w/o anticoagulant/IPC | ACCP Px received | ACCP anticoagulant | ACCP GCS w/o anticoagulant/IPC |
---|---|---|---|---|---|---|
 | (%) | ntn (%)* | n (%)* | N (%) | n (%)* | n (%)* |
Surgical Patients at VTE Risk | Â | Â | Â | Â | Â | Â |
Hip replacement | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Knee replacement | 1 (50.0%) | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Hip fracture | 6 (100.0%) | 6 (100.0%) | 0 (0.0%) | 6 (100.0%) | 6 (100.0%) | 0 (0.0%) |
Curative arthroscopy | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Other ortho trauma | 13 (56.5%) | 13 (100.0%) | 0 (0.0%) | 11 (47.8%) | 11 (100.0%) | 0 (0.0%) |
Colon/small bowel | 8 (42.1%) | 8 (100.0%) | 0 (0.0%) | 8 (42.1%) | 8 (100.0%) | 0 (0.0%) |
Rectosigmoid | 4 (100.0%) | 3 (75.0%) | 1 (25.0%) | 3 (75.0%) | 3 (100.0%) | 0 (0.0%) |
Gastric | 4 (50.0%) | 4 (100.0%) | 0 (0.0%) | 4 (50.0%) | 4 (100.0%) | 0 (0.0%) |
Hepatobiliary | 7 (21.2%) | 6 (85.7%) | 1 (14.3%) | 7 (21.2%) | 6 (85.7%) | 1 (14.3%) |
Urologic | 5 (26.3%) | 5 (100.0%) | 0 (0.0%) | 5 (26.3%) | 5 (100.0%) | 0 (0.0%) |
Vascular | 6 (54.5%) | 5 (83.3%) | 1 (16.7%) | 6 (54.5%) | 5 (83.3%) | 1 (16.7%) |
Thoracic | 2 (50.0%) | 2 (100.0%) | 0 (0.0%) | 2 (50.0%) | 2 (100.0%) | 0 (0.0%) |
Gynecologic | 5 (50.0%) | 5 (100.0%) | 0 (0.0%) | 5 (50.0%) | 5 (100.0%) | 0 (0.0%) |
Other surgery | 22 (28.2%) | 20 (90.9%) | 1 (4.5%) | 20 (25.6%) | 20 (100.0%) | 0 (0.0%) |
Major trauma but surgery not performed | 3 (33.3%) | 3 (100.0%) | 0 (0.0%) | 3 (33.3%) | 3 (100.0%) | 0 (0.0%) |
Medical Patients at VTE Risk | Â | Â | Â | Â | Â | Â |
Acute heart failure (NYHA Class III or IV) | 12 (40.0%) | 11 (91.7%) | 0 (0.0%) | 9 (30.0%) | 9 (100.0%) | 0 (0.0%) |
Ischemic stroke | 12 (63.2%) | 12 (100.0%) | 0 (0.0%) | 12 (63.2%) | 12 (100.0%) | 0 (0.0%) |
Hemorrhagic stroke | 2 (66.7%) | 2 (100.0%) | 0 (0.0%) | 2 (66.7%) | 2 (100.0%) | 0 (0.0%) |
Other cardiovascular disease | 36 (57.1%) | 34 (94.4%) | 0 (0.0%) | 32 (50.8%) | 32 (100.0%) | 0 (0.0%) |
Hematologic disease | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Malignancy (active) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Acute non-infectious respiratory disease | 4 (16.7%) | 3 (75.0%) | 1 (25.0%) | 3 (12.5%) | 3 (100.0%) | 0 (0.0%) |
Pulmonary infection | 22 (29.7%) | 20 (90.9%) | 0 (0.0%) | 20 (27.0%) | 20 (100.0%) | 0 (0.0%) |
Infection (non-respiratory) | 3 (25.0%) | 3 (100.0%) | 0 (0.0%) | 2 (16.7%) | 2 (100.0%) | 0 (0.0%) |
Rheumatotologic/Inflammatory | 1 (25.0%) | 1 (100.0%) | 0 (0.0%) | 1 (25.0%) | 1 (100.0%) | 0 (0.0%) |
Neurologic | 3 (37.5%) | 3 (100.0%) | 0 (0.0%) | 3 (37.5%) | 3 (100.0%) | 0 (0.0%) |
Renal | 7 (35.0%) | 7 (100.0%) | 0 (0.0%) | 7 (35.0%) | 7 (100.0%) | 0 (0.0%) |
Endocrine/Metabolic | 19 (44.2%) | 17 (89.5%) | 0 (0.0%) | 17 (39.5%) | 17 (100.0%) | 0 (0.0%) |
GI/Hepatobiliary | 5 (20.8%) | 5 (100.0%) | 0 (0.0%) | 5 (20.8%) | 5 (100.0%) | 0 (0.0%) |
Other medical condition | 2 (50.0%) | 2 (100.0%) | 0 (0.0%) | 2 (50.0%) | 2 (100.0%) | 0 (0.0%) |